Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-09-26
2006-09-26
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S463000
Reexamination Certificate
active
07112581
ABSTRACT:
Compounds represented by the following structure (I), acid-addition salts and pro-drugs are disclosed:wherein the ring structure includes no substitutions, one substitution, or more than one substitution; and wherein n is equal to an integer grater than 1, preferably 2, 3, or 4; m is equal to a positive integer, preferably 1, 2 or 3, and each separate Xnand X are each separately selected from a nucleophilic residue, preferably —H, —OH, —O—CO-alkyl, —O-alkyl, —NH2, a halogen and the like; and wherein the dashed line represents a C—C bond or a C—H bond, and the dashed and solid line represents either a carbon-carbon single bond or a carbon-carbon double bond.
REFERENCES:
patent: 5445829 (1995-08-01), Paradissis et al.
patent: 5565561 (1996-10-01), Müller et al.
patent: 5576012 (1996-11-01), Baver et al.
patent: 5601845 (1997-02-01), Buxton et al.
patent: 5641515 (1997-06-01), Ramtoola
patent: 5653987 (1997-08-01), Modi et al.
patent: 5654286 (1997-08-01), Hostetler
patent: 5667809 (1997-09-01), Trevino et al.
patent: 5683676 (1997-11-01), Akehurst et al.
patent: 5688529 (1997-11-01), Lidgate et al.
patent: 5707615 (1998-01-01), Cardin et al.
patent: 5707641 (1998-01-01), Gertner et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5733888 (1998-03-01), Carver et al.
patent: 5874443 (1999-02-01), Kiely et al.
patent: 5886210 (1999-03-01), Rayle et al.
patent: 5992683 (1999-11-01), Sigl
patent: 6350759 (2002-02-01), Casara et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6509331 (2003-01-01), Audia et al.
patent: WO 99/07692 (1999-02-01), None
patent: WO 00/37473 (2000-06-01), None
Faulkner, D. John, “Marine Pharmacology”, Antonie van Leeuwnhoek, vol. 77, pp. 135-145 (2000).
Fenical, William, et al., “Marine Microorganisms as a Developing Resource for Drug Discovery”, Pharmaceutical News, vol. 9, pp. 489-494 (2002).
Gerber, Nancy N., “A New Prodiginine(Prodigiosin-like)Pigment from Streptomyces. Antimalarial Activity of Several Prodiginines”, The Journal of Antibiotics, vol. XXVIII, No. 3, pp. 194-199 (Mar., 1975).
Kojiri, Katsuhisa, et al., “A New Macrocyclic Lactam Antiobiotic, VE-14106, I. Taxonomy, Isolation, Biological Activity and Structural Elucidation”, The Journal of Antibiotics, vol. 45, No. 6, pp. 868-874 (Jun. 1992).
Okami, Yoshiro, “The Search for Bioactive Metabolites from Marine Bacteria”, The Journal of Marine Biotechnology, vol. 1, pp. 59-65 (1993).
Shindo, Kazutoshi, et al., “Vicenistatin, a Novel 20-Membered Macrocyclic Lactam Antitumor Antibiotic”, The Journalo of Antibiotics, vol. 46, No. 7, pp. 1076-1081.
Takahashi, I., et al., “Communication to the Editor”, The Journal of Antibiotics, vol. 50, No. 2, 186-188.
Wasserman, Harry H., et al.,Journal of the American Chemical Society; vol. 91, No. 5, pp. 1263-1264 (Feb. 1969).
Arai, et al. “Absolute Stereochemistry of Vicenistatin, a Novel 20-Membered Macrocyclic Lactam Antitumor Antibiotic.” Tetrahedron Letters. 39: 3181-3184 (1998).
International Search Report for International Application No. PCT/US 03/30518 dated May 25, 2004.
Alm, et al. “Effects of topically Applied PGF2αand its Isopropylester on Normal and Glaucomatous Human Eyes.”Prog. Coin. Biol. Res.312:447-58 (1998).
“Bioreversible Carriers in Drug Design: Theory and Application,” edited by E. B. Roche, Pergamon Press: New York, 14-21 (1987).
Fenical, William. “Chemical Studies of Marine Bacteria: Developing a New Resource.”Chem. Rev.93:1673-1683 (1993).
Fingl, et al. Basis of Therapeutics. 5thEdition. Macmillan Publishing Co. Chp. 13. “Drugs Effective in the Therapy of the Epilepsies,” (1975).
Fingl, et al. Basis of Therapeutics. 5thEdition. Macmillan Publishing Co. Chp. 17. “Analgesic-Antipyretics, Anti-Inflammatory Agents, and Drugs Employed in the Therapy of Gout,” (1975).
Fingl, Edward. Basis of Therapeutics. 5thEdition. Macmillan Publishing Co. Chp. 49. “Laxatives and Cathartics,” (1975).
Higuchi, et al. “Pro-drugs as Novel Delivery Systems.” A.C.S. Symposium Series, American Chemical Society. 14(3): 154-183 (1975).
Joshi, A. “Microparticulates for Ophthalmic Drug Delivery.”J. Ocul. Pharmacol., 10(1):29-45 (1994).
Khokhlova, et al. “A Chemical Study of the Major Vitamycin Component.” Institute of Microbiology, Academy of Sciences of the USSR, Moscow, pp. 841-845, Russian (1964).
Krassilnikov, et al. “A New Species in the Group of Actinomyces Aurantiacus,” pp. 482-489 (1960).
Mayer et al. “Efficacy of a Novel Hydrogel Formulation in Human Volunteers.”Ophthalmologica.210(2):101-3 (1996).
Mordenti, et al. “Intraocular Pharmacokinetics and Safety of a Humanized Monocional Antibody in Rabbits after Intravitreal Administration of a Solution or a PLGA Microsphere Formulation.”Toxicol. Sci.52(1):101-6 (1999).
Shedden, et al. “Efficacy and Tolerability of Timolol Maleate Ophthalmic Gel-Forming Solution Versus Timolol Ophthalmic Solution in Adults with Open-Angle Glaucoma or Ocular Hypertension: A Six-Month, Double-Masked, Multicenter Study.”Clin. Ther, 23(3):440-50 (2001).
Mitchell Scott C.
Nicholson Benjamin
Kifle Bruck
Knobbe Martens Olson & Bear LLP
Nereus Pharmaceuticals Inc.
LandOfFree
Macrocyclic lactams does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Macrocyclic lactams, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic lactams will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3555016